WO2005070413A1 - レチノイン酸を含有する糖尿病治療薬 - Google Patents
レチノイン酸を含有する糖尿病治療薬 Download PDFInfo
- Publication number
- WO2005070413A1 WO2005070413A1 PCT/JP2005/000743 JP2005000743W WO2005070413A1 WO 2005070413 A1 WO2005070413 A1 WO 2005070413A1 JP 2005000743 W JP2005000743 W JP 2005000743W WO 2005070413 A1 WO2005070413 A1 WO 2005070413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retinoic acid
- diabetes
- acid
- composite particles
- inorganic
- Prior art date
Links
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 title claims abstract description 98
- 229930002330 retinoic acid Natural products 0.000 title claims abstract description 96
- 229960001727 tretinoin Drugs 0.000 title claims abstract description 92
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims abstract description 9
- 239000011246 composite particle Substances 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 28
- 229910052751 metal Inorganic materials 0.000 claims description 16
- 239000002184 metal Substances 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- -1 inorganic acid salt Chemical class 0.000 claims description 14
- 210000000952 spleen Anatomy 0.000 claims description 13
- 229920002988 biodegradable polymer Polymers 0.000 claims description 8
- 239000004621 biodegradable polymer Substances 0.000 claims description 8
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- 239000008103 glucose Substances 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 15
- 230000003914 insulin secretion Effects 0.000 abstract description 10
- 150000003839 salts Chemical class 0.000 abstract description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 5
- 229940002612 prodrug Drugs 0.000 abstract description 2
- 239000000651 prodrug Substances 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 46
- 241000700159 Rattus Species 0.000 description 39
- 102000004877 Insulin Human genes 0.000 description 23
- 108090001061 Insulin Proteins 0.000 description 23
- 229940125396 insulin Drugs 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000000693 micelle Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 235000001465 calcium Nutrition 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007334 copolymerization reaction Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940122199 Insulin secretagogue Drugs 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 239000004246 zinc acetate Substances 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical compound CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000270914 Pelobatidae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 150000001218 Thorium Chemical class 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940125690 blood glucose regulator Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a drug for preventing and / or treating diabetes or a disease related thereto, which comprises retinoic acid as an active ingredient. More specifically, it relates to a diabetic drug that not only controls blood glucose levels but also acts directly on ⁇ cells of the spleen.
- Diabetes is defined as ⁇ a group of metabolic disorders characterized by chronic hyperglycemia due to insufficient insulin action '' (Report of the Japanese Diabetes Association, Committee on Diagnosis Classification and Diagnostic Criteria, 1999) Insulin deficiency, mainly due to the depletion of insulin-deficient ⁇ cells in the spleen that secretes insulin for some reason, as well as the reduced insulin secretion of the spleen and insufficient effects of insulin are combined with type II diabetes, which is caused by a combination of various conditions (insulin resistance). If hyperglycemia persists, it can cause retinopathy, nephropathy, and neuropathy, which are the three major complications of diabetes, as well as severe conditions such as stroke and myocardial infarction.
- Non-Patent Document 1 In addition to oral drugs such as (SU) drugs and diabetes treatments mainly consisting of insulin preparations, it also inhibits gluconeogenesis and release in the liver and uses glucose in skeletal muscle and fat cells based on a new mechanism of action.
- BG gluconeogenesis drugs that promote glucose and storage
- a-darcosidase inhibitors that reduce intestinal glucose absorption
- insulin action enhancers insulin action enhancers
- NN-623, AY4166, and the like as novel insulin secretagogues other than the above SU agent are known as agents directly acting on ⁇ cells of the spleen (Non-patent Document 1).
- Non-Patent Document 1 Masao Ota, Nichidai Journal, 1999, Vol. 66, No. 3, pp. 39_42
- the present inventors have been independently conducting research on retinoic acid, and have found for the first time to restore spleen function when retinoic acid is administered in vivo, and have accomplished the present invention. .
- the present invention provides a therapeutic and / or prophylactic agent for diabetes containing retinoic acid as an active ingredient, thereby solving the above-mentioned problems.
- the medicament for treating and / or preventing diabetes according to the present invention is considered to act directly on the spleen ( ⁇ 8 cells) to regenerate its function. Therefore, the medicament of the present invention is effective not only for blood glucose level regulation in insulin-resistant type II diabetes patients but also for type I diabetes patients in which ⁇ cells are destroyed.
- the blood sugar level can be maintained in an appropriate range, and thus it is useful for prevention and treatment of various complications associated with hyperglycemia. Is also effective.
- FIG. 1 is a graph showing changes in body weight of diabetic rats with and without retinoic acid administration.
- A Rats receiving retinoic acid (6 mg);
- B Rats receiving retinoic acid inorganic substance (CaCo) composite particles (6 mg)
- FIG. 2 Diabetic rats to which retinoic acid-inorganic substance composite particles (LA / CaCo) (6 mg) were administered, and
- FIG. 1 is a photograph showing the appearance of a diabetic rat on day 100, and that of a control (no LA administration) diabetic rat.
- FIG. 3 is a graph showing (a) changes in body weight, (b) changes in plasma insulin concentration, and (c) changes in blood glucose concentration in diabetic rats with and without retinoic acid administration.
- Reference Rats administered with retinoic acid organic substance (PLGA) composite particles (6 mg); Country: Control rats (without administration of retinoic acid).
- PLGA retinoic acid organic substance
- FIG. 4 is a graph showing changes in plasma insulin concentration in diabetic rats with and without retinoic acid administration.
- RA retinoic acid-administered rats
- Ra-Ca retinoic acid inorganic substance (CaCo) composite particles
- RA-PLGA Rat administered retinoic acid organic substance (PLGA) composite particles; Control: Rat administered no retinoic acid. The numerical value in the sword indicates the dose.
- the medicament of the present invention is characterized by containing retinoic acid as an active ingredient.
- Retinoic acid is a fat-soluble small molecule derived from vitamin A, and the major isomers are all-trans-retinoic acid and 9-cis-retinoic acid.
- all-trans-retinoic acid (aU-trans retinoic acid) represented by the following formula (I) is preferably used.
- retinoic acid has a differentiation-inducing effect on undifferentiated cells and exerts a morphogen-like effect on morphogenesis.
- This differentiation-inducing crop Is used clinically as a therapeutic drug for acute promyelocytic leukemia (APL).
- APL acute promyelocytic leukemia
- JP 2001-299335 A JP 2001-299335 A.
- retinoic acid regulates the differentiation of undifferentiated cells of higher organisms and regenerates spleen during embryonic development.
- conventional research targets all tissues ( It is a totipotent embryonic stem cell that has the potential to divide into organs), and no knowledge has been obtained on how retinoic acid acts on somatic stem cells derived from each organ in vivo. Absent.
- the present invention is based on a new finding that it can act on the spleen in vivo by retinoic acid power to restore the insulin secretion ability of j8 cells and improve the blood glucose control function!
- the retinoic acid used as the active ingredient of the medicament of the present invention is preferably all-trans-retinoic acid represented by the above formula (I), but isomers, esters and other derivatives, salts, or prodrugs thereof. It may be.
- retinoic acid may be added as it is, but composite particles of an appropriate inorganic or organic substance and retinoic acid are prepared, and the retinoic acid composite particles are added as an active ingredient. I also like to do ⁇ .
- Retinoic acid composite particles include particles that are surface-modified with an inorganic substance such as calcium or zinc carbonate or phosphate, or an organic substance such as a biodegradable polymer, and solid particles that are integrally formed with the substance.
- These retinoic acid composite particles should have a form in which the whole or a part of the surface of retinoic acid is coated with an inorganic or organic substance, or a form in which retinoic acid is dispersed inside solid particles made of inorganic or organic substance.
- the retinoic acid-inorganic substance composite particles can be prepared, for example, by utilizing the amphiphilicity of retinoic acid. Specifically, calcium carbonate was selected as the inorganic substance.
- retinoic acid is dispersed in an alkaline aqueous medium with a small amount of a polar organic solvent to form spherical micelles whose surface is covered with a negative charge.
- a nonionic surfactant to form a mixed micelle of retinoic acid and the nonionic surfactant, aggregation and precipitation of micelles can be prevented.
- calcium chloride calcium ions (Ca 2+ ) are adsorbed to the minus charge on the micelle surface to form micelles having a spherical or oval shape covered with calcium ions having a surface force. Then add sodium carbonate and add inorganic acid such as carbonate ion (CO 2 ).
- a calcium carbonate film is formed on the surface of the retinoic acid particles, and retinoic acid composite particles surface-modified with an inorganic substance are obtained.
- polar solvents used when dispersing retinoic acid include ethanol, methanol, acetone, ethyl acetate, dimethyl sulfoxide and the like. , Ethanol or methanol is preferred.
- inorganic salts of polyvalent metals such as calcium, magnesium, and zinc, particularly divalent metals, for example, carbonates and phosphates, are used. I prefer to.
- the polyvalent metal is added in the form of chloride, acetate, halide and the like, for example, calcium chloride, magnesium chloride, zinc acetate and the like.
- the inorganic acid is added in the form of an alkali metal salt, for example, sodium carbonate, sodium phosphate and the like.
- the weight ratio of the polyvalent metal (chloride salt or the like) to the inorganic thorium salt or the like to be added is 1: 1.
- the ratio is 0.05 to 0.33, preferably 1: 0.2, it is possible to obtain a transparent aqueous suspension of retinoic acid-inorganic substance composite particles having a particle size of about 5-100 nm.
- a polyvalent metal salt such as calcium chloride and an inorganic acid such as carbonic acid or phosphoric acid are added.
- a polyvalent metal salt such as calcium chloride and an inorganic acid such as carbonic acid or phosphoric acid are added.
- composite particles nanoparticles having an average particle size of about 5 to 300 nm could be prepared.
- Such composite particles having a small particle size on the order of nanometers are particularly preferable when retinoic acid is administered subcutaneously or intravenously, or when it is dermally applied (applied, etc.) and transdermally absorbed.
- the polyvalent metal inorganic acid salt such as calcium carbonate formed on the micelle surface by the above method has an amorphous or metastable phaselite structure having a V ⁇ ⁇ glass structure, and therefore has a film structure. Has high solubility in water, improves biodegradability, and is easily decomposed. As a result, when the obtained calcium retinoic acid carbonate composite particles are administered into a living body or the like, the calcium carbonate coating layer on the micelle surface is easily decomposed, and the contained retinoic acid is released. It was confirmed that the drug effect can be exerted in a sustained release manner.
- retinoin when an aqueous suspension of calcium retinoic acid carbonate composite particles is injected subcutaneously into rats, or when the composite particles are applied to the skin surface together with a vaseline base, retinoin does not cause tumor formation at the administration site. The absorption was much better than when using the acid alone.
- composite particles of an organic substance and retinoic acid can be formed into general particles using a biodegradable polymer such as lactic acid-Z-glycolic acid copolymer (PLGA) or polylactic acid (PGA). It can be prepared according to the method (in-liquid drying method). Specifically, retinoic acid is dispersed in a halogenated hydrocarbon solution of a biodegradable polymer polyvalent metal salt, and the obtained dispersion is dispersed in a polybutyl alcohol aqueous solution and the like, and the halogenated hydrocarbon is evaporated. The particles are prepared by washing the particles with distilled water or the like.
- a biodegradable polymer such as lactic acid-Z-glycolic acid copolymer (PLGA) or polylactic acid (PGA).
- PLGA lactic acid-Z-glycolic acid copolymer
- PGA polylactic acid
- lactic acid-Z glycolic acid copolymer used as the biodegradable polymer, a D-isomer, an L-integrated body, and a mixture thereof are preferably used as a racemic form.
- the copolymerization ratio of the lactic acid Z-glycolic acid copolymer (lactic acid Z-glycolic acid; mol%) is about 95Z5-45.
- Z55 force S preferred. More preferably, it is 90Z10-45Z55. Its weight-average molecular weight is about 3,000-20,000 force S preferred ⁇ , and more preferred ⁇ 3,000- 15,000.
- the degree of dispersion (weight average molecular weight, Z number average molecular weight) of the fuco L-acid Z-dalicholate copolymer is about 1.2 to 4.0, preferably about 1.2 to 2.5.
- These copolymers are synthesized according to a method known per se. Especially, what was manufactured by the non-catalytic dehydration condensation method is preferable.
- two or more lactic acid-Z-glycolic acid copolymers having different copolymerization ratios and different weight average molecular weights may be mixed and used at an arbitrary ratio.
- a mixture of a copolymer having a copolymerization ratio of 50Z50 and a weight average molecular weight of about 6,000 and a copolymer having a copolymerization ratio of 50Z50 and a weight average molecular weight of about 3,000 are used.
- An appropriate weight ratio when mixing is 75Z25 to 25Z75.
- the weight average molecular weight and the number average molecular weight in the present specification mean values measured by gel permeation chromatography using polystyrene as a standard substance.
- the salt of the polyvalent metal used together with the biodegradable polymer or its oxidized product may be a metal salt or a metal oxidized product that does not adversely affect the living body. It is not particularly limited. Alkaline earth metals (calcium, magnesium, etc.), zinc, iron, copper, tin, aluminum, etc. and salts of inorganic acids or organic acids, or oxides of these metals are used. As the metal, preferably, an alkaline earth metal, zinc, iron, or aluminum, particularly zinc or calcium is used.
- the inorganic acid include hydrochloric acid, sulfuric acid, nitric acid, and thiocyanic acid.
- organic acids aliphatic carboxylic acids and aromatic carboxylic acids are used.
- halogenated hydrocarbon as a solvent, a chlorinated saturated hydrocarbon having 1 or 2 carbon atoms and a fluorinated saturated hydrocarbon having 1 or 2 carbon atoms are preferably used. Specific examples of these include chloroform, methylene chloride, 1,2-dichloroethane, 1,1-dichloromethane, monofluoromethane, difluoromethane and the like.
- the solution is prepared based on the total weight of the biodegradable polymer, the salt of the polyvalent metal or the oxidized product thereof, and the halogenated hydrocarbon, based on the total weight of the biodegradable polymer and the polyvalent metal.
- the dashi is preferably contained in an amount of 10-90% by weight and 0.01-3% by weight, more preferably 30-80% by weight and 0.01-2% by weight, respectively.
- other organic solvents miscible with water for example, an aliphatic organic compound having 13 hydroxyl groups may be used in place of the polybutyl alcohol. Examples include glycerin, polyethylene glycol, propylene glycol, ethyl alcohol, isopropyl alcohol, benzyl alcohol and the like.
- the medicament of the present invention is usually provided in the form of a composition obtained by mixing retinoic acid or retinoic acid composite particles with an inorganic or organic substance and a pharmacologically acceptable carrier.
- a pharmacologically acceptable carrier various organic or inorganic carrier substances commonly used in the pharmaceutical field can be used.
- a medium such as water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, or cottonseed oil contains retinoic acid.
- the retinoic acid composite particles are dispersed or dissolved.
- an aqueous suspension in which retinoic acid is dispersed in an aqueous medium is preferable.
- Liquid preparations may contain, in addition to the vehicles mentioned above, additional components such as solubilizing agents, suspending agents, isotonic agents, buffers, preservatives, antioxidants, and the like.
- the medicament of the present invention may be provided in the form of a solid preparation such as a freeze-dried preparation of the above liquid preparation or a solidified preparation of an active ingredient, which is suitable for use at the time of use. It may be dispersed or dissolved to prepare an injection solution. In the case of a solid preparation, additional components such as an excipient, a binder, and a disintegrant may be added.
- a solid preparation such as a freeze-dried preparation of the above liquid preparation or a solidified preparation of an active ingredient, which is suitable for use at the time of use. It may be dispersed or dissolved to prepare an injection solution.
- additional components such as an excipient, a binder, and a disintegrant may be added.
- the dosage form of the medicament of the present invention is usually a liquid form intended for a liquid preparation such as an injection solution as described above, but depending on the administration method, an external preparation (such as an ointment), a suppository, or a pellet may be used. It can also be made into parenteral preparations such as nasal preparations and inhalants, or oral preparations such as capsules.
- the medicament of the present invention thus prepared is useful for preventing and treating diabetes (including type I diabetes and type II diabetes), and for preventing and treating various diseases associated with hyperglycemia. Z or effective for treatment.
- the dosage of the medicament of the present invention varies depending on the administration patient, administration route, symptoms and the like.
- retinoic acid as an active ingredient is usually administered in an amount of about 1 kg / kg body weight. It is preferable to administer 0.01 to 100 mgZkg, preferably 0.05 to 30 mg, more preferably 0.1 to 10 mg as a single dose, and to administer this amount once to three times a day.
- the medicament of the present invention is characterized by directly acting on ⁇ cells of the spleen to improve diabetes and return blood glucose levels to normal, and develop a hypoglycemic state like a conventional blood glucose regulator. It seems that the risk is low. Therefore, it may be used in combination with conventional drugs intended to regulate blood glucose levels, such as insulin preparations, insulin sensitizers, ⁇ -dalcosidase inhibitors, biguanides, and insulin secretagogues (SU agents).
- conventional drugs intended to regulate blood glucose levels such as insulin preparations, insulin sensitizers, ⁇ -dalcosidase inhibitors
- retinoic acid commercially available retinoic acid (solid particles) was used as it was.
- retinoic acid 13.6 mg was dissolved in 900 L of ethanol (or methanol), and 100 / z L of a 0.5N-NaOH aqueous solution was added to this solution. The pH at this time was 7-7.5.
- 100 L was collected, added to 100 L of distilled water containing Tween 80 (trade name), and stirred well. Approximately 30 minutes later, an aqueous solution containing 5M-shiridani calcium was added and stirred, and further 30 minutes later, an aqueous solution containing 1M-sodium carbonate was added and further stirred. After continuing stirring all day and night, the obtained solution was freeze-dried overnight to prepare the desired calcium retinoate carbonate composite particles.
- PLGA (7.16 g), ZnO (40 mg) and retinoic acid (800 mg) were put into dichloromethane and uniformly dispersed with a vortex mixer. Thereafter, the above solution was poured from a vial into distilled water (1600 mL) in which 16 g of polybutyl alcohol (molecular weight: 450,000) and 11.2 g of zinc acetate were dissolved, and the mixture was stirred for about 3 hours. Was evaporated. Particles formed by the evaporation of dichloromethane were separated from distilled water using a centrifuge. The particles separated as a precipitate were washed several times with distilled water, and then wet-filtered with a sieve of 125 m to uniform the particle size. Finally, it was dried for about 24 hours in a freeze dryer.
- the retinoic acid composite particles with the retinoic acid and the inorganic and organic substances prepared as described above were dispersed in physiological saline at a predetermined concentration (3 to 12 mg ZmL) to prepare an injection solution.
- Example 2 [0034] The injection solution (containing 6 mg of retinoic acid) prepared in Example 1 was subcutaneously injected into the back of a diabetic rat by using a syringe equipped with an 18-21 gauge injection needle. When an 18 gauge needle was used, the site was sealed with surgical Aaron Alpha (trade name) after injection to prevent fluid leakage.
- FIG. 2 shows photographs showing the appearance of rats administered with retinoic acid (inorganic substance composite particles) 100 days after the start of measurement and control rats (without administration of retinoic acid). It can be seen that while the control rats are losing weight due to weight loss, the rats receiving retinoic acid recovered by suppressing weight loss. The same tendency was observed when the dose of retinoic acid was changed to 3 mg or 12 mg.
- Example 2 the weight of the diabetic rat to which the retinoic acid organic substance (PLGA) composite particles (6 mg) had been administered and the diabetic rat of the control (without administration of retinoic acid) up to about day 40 were observed.
- the changes are shown in Fig. 3 (a), and the changes in plasma insulin concentration and blood dalcos concentration in each rat at the same time are shown in Figs. 3 (b) and (c).
- the reference symbol indicates rats administered with retinoic acid organic substance (PLGA) composite particles (6 mg), and the country indicates control rats (without administration of retinoic acid).
- retinoic acid Since retinoic acid has no effect of directly stimulating insulin secretion, administration of retinoic acid restores the function of splenic ⁇ -cells and increases blood glucose concentration by improving insulin secretion activity. It can be considered that the symptoms of diabetes have been alleviated.
- FIG. 4 shows a comparison of changes in the plasma insulin concentration of rats under each condition before and after administration of retinoic acid. Comparing the values before and on day 42 after administration, the control rats without retinoic acid showed no change in insulin concentration, whereas the rats receiving retinoic acid showed no change under any conditions. Insulin levels increased compared to before administration. At 141 days after the administration, the insulin level of the administered rats tended to be higher than that of the control rats.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005517270A JPWO2005070413A1 (ja) | 2004-01-23 | 2005-01-21 | レチノイン酸を含有する糖尿病治療薬 |
US10/586,775 US20080274193A1 (en) | 2004-01-23 | 2005-01-21 | Retinoic Acid-Containing Antidiabetic Agent |
EP05709250A EP1707195A4 (en) | 2004-01-23 | 2005-01-21 | RETINOLIC ACID KEEPING REMEDY FOR DIABETES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-015236 | 2004-01-23 | ||
JP2004015236 | 2004-01-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005070413A1 true WO2005070413A1 (ja) | 2005-08-04 |
Family
ID=34805448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/000743 WO2005070413A1 (ja) | 2004-01-23 | 2005-01-21 | レチノイン酸を含有する糖尿病治療薬 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080274193A1 (ja) |
EP (1) | EP1707195A4 (ja) |
JP (1) | JPWO2005070413A1 (ja) |
CN (1) | CN1921843A (ja) |
WO (1) | WO2005070413A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1878425A1 (en) * | 2005-04-28 | 2008-01-16 | Japan Science and Technology Agency | Transdermal absorption accelerator |
US20110065781A1 (en) * | 2007-12-14 | 2011-03-17 | Ezaki Glico Co., Ltd. | Alpha-LIPOIC ACID NANOPARTICLES AND METHODS FOR PREPARING THEREOF |
JP2011219439A (ja) * | 2010-04-14 | 2011-11-04 | Tottori Univ | レチノイン酸受容体リガンドによるインスリン抵抗性改善作用 |
US8236855B2 (en) * | 2007-05-17 | 2012-08-07 | Case Western Reserve University | Methods of treating metabolic disorders |
JP2014506457A (ja) * | 2011-01-25 | 2014-03-17 | エス.エイチ.コー ミノル | 膵臓幹細胞及び前駆細胞のためのマーカーとしてのzscan4及びその使用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008081427A (ja) * | 2006-09-27 | 2008-04-10 | R&R Inc | 分泌障害性疾患の予防及び/又は治療のための医薬 |
CN102727477B (zh) * | 2012-06-14 | 2014-07-16 | 合肥博太医药生物技术发展有限公司 | 视黄酸及其衍生物在制备防治糖尿病药物中的应用 |
US10105334B2 (en) | 2014-01-17 | 2018-10-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus |
CN105641687A (zh) * | 2016-01-14 | 2016-06-08 | 李华红 | 一种复方降糖药物组合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11511472A (ja) * | 1995-09-18 | 1999-10-05 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Rxrアゴニストを用いたniddmの治療 |
JP2001521551A (ja) * | 1997-03-24 | 2001-11-06 | ガルデルマ リサーチ アンド デヴェロップメント エス エヌ セ | インスリン非依存性糖尿病の治療のためのレチノイド関連分子 |
WO2002017901A2 (en) * | 2000-08-30 | 2002-03-07 | The Brigham And Women's Hospital, Inc. | Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
WO2002080936A1 (en) * | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
JP2004163379A (ja) * | 2002-11-11 | 2004-06-10 | Research Foundation Itsuu Laboratory | 糖尿病の診断方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2723315B1 (fr) * | 1994-08-02 | 1996-10-25 | Cird Galderma | Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes |
CA2204616C (en) * | 1995-09-18 | 2002-12-17 | Ranjan Mukherjee | Ppar gamma antagonists for treating obesity |
EP0908179A1 (en) * | 1997-08-23 | 1999-04-14 | Werner Bollag | Treatment of cell-mediated immune diseases |
-
2005
- 2005-01-21 US US10/586,775 patent/US20080274193A1/en not_active Abandoned
- 2005-01-21 EP EP05709250A patent/EP1707195A4/en not_active Withdrawn
- 2005-01-21 CN CNA2005800054354A patent/CN1921843A/zh active Pending
- 2005-01-21 WO PCT/JP2005/000743 patent/WO2005070413A1/ja active Application Filing
- 2005-01-21 JP JP2005517270A patent/JPWO2005070413A1/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11511472A (ja) * | 1995-09-18 | 1999-10-05 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Rxrアゴニストを用いたniddmの治療 |
JP2001521551A (ja) * | 1997-03-24 | 2001-11-06 | ガルデルマ リサーチ アンド デヴェロップメント エス エヌ セ | インスリン非依存性糖尿病の治療のためのレチノイド関連分子 |
WO2002017901A2 (en) * | 2000-08-30 | 2002-03-07 | The Brigham And Women's Hospital, Inc. | Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma |
WO2002080936A1 (en) * | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
JP2004163379A (ja) * | 2002-11-11 | 2004-06-10 | Research Foundation Itsuu Laboratory | 糖尿病の診断方法 |
Non-Patent Citations (2)
Title |
---|
NANZANDO ET AL: "Igaku Daijiten Gokaban 18th edition", 16 January 1998, pages: 1486 - 1487, XP002997684 * |
See also references of EP1707195A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1878425A1 (en) * | 2005-04-28 | 2008-01-16 | Japan Science and Technology Agency | Transdermal absorption accelerator |
EP1878425A4 (en) * | 2005-04-28 | 2009-08-26 | Japan Science & Tech Agency | TRANSDERMAL ABSORPTION ACCELERATOR |
US9095560B2 (en) | 2005-04-28 | 2015-08-04 | Japan Science And Technology Agency | Method of enhancing transdermal absorption using a composition comprising POE octyl dodecyl ether and squalane |
US8236855B2 (en) * | 2007-05-17 | 2012-08-07 | Case Western Reserve University | Methods of treating metabolic disorders |
US8815947B2 (en) | 2007-05-17 | 2014-08-26 | Case Western Reserve University | Methods of treating metabolic disorders |
US20110065781A1 (en) * | 2007-12-14 | 2011-03-17 | Ezaki Glico Co., Ltd. | Alpha-LIPOIC ACID NANOPARTICLES AND METHODS FOR PREPARING THEREOF |
JP2011063606A (ja) * | 2007-12-14 | 2011-03-31 | Ezaki Glico Co Ltd | α−リポ酸ナノ粒子およびその調製方法 |
US9079874B2 (en) | 2007-12-14 | 2015-07-14 | Ezaki Glico Co., Ltd. | α-Lipoic acid nanoparticles and methods for preparing thereof |
JP2011219439A (ja) * | 2010-04-14 | 2011-11-04 | Tottori Univ | レチノイン酸受容体リガンドによるインスリン抵抗性改善作用 |
JP2014506457A (ja) * | 2011-01-25 | 2014-03-17 | エス.エイチ.コー ミノル | 膵臓幹細胞及び前駆細胞のためのマーカーとしてのzscan4及びその使用 |
US10273458B2 (en) | 2011-01-25 | 2019-04-30 | Elixirgen, Llc | ZSCAN4 as a marker for pancreatic stem cells and progenitor cells and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1707195A4 (en) | 2007-06-20 |
CN1921843A (zh) | 2007-02-28 |
JPWO2005070413A1 (ja) | 2007-09-06 |
US20080274193A1 (en) | 2008-11-06 |
EP1707195A1 (en) | 2006-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005070413A1 (ja) | レチノイン酸を含有する糖尿病治療薬 | |
JP3903061B2 (ja) | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 | |
CN103327986B (zh) | 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法 | |
JP4881385B2 (ja) | スタチン封入ナノ粒子含有医薬組成物 | |
Jaferian et al. | Colon cancer targeting using conjugates biomaterial 5-flurouracil | |
EP3104844B1 (en) | Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
CN104736158A (zh) | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 | |
JP2961045B2 (ja) | 腸管粘膜増強促進剤 | |
EA017290B1 (ru) | Композиции на основе ганаксолона | |
US10154968B2 (en) | Buprenorphine nanoparticle composition and methods thereof | |
Puntel et al. | Prolonged prevention of retinal degeneration with retinylamine loaded nanoparticles | |
WO2018108163A1 (zh) | 一种Talazoparib药物组合物及其应用 | |
CN109730966B (zh) | 一种壳寡糖修饰的自携式无载体鼻腔纳米制剂脑靶向递送系统及其制备方法 | |
WO2023221320A1 (zh) | 一种改进的低毒高效原酸酯混溶物药用辅料、制备方法、包含该辅料的局部缓释给药制剂 | |
US20160045439A1 (en) | Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same | |
CN112121028B (zh) | 一种辛伐他汀固体纳米粒制剂及其制备方法 | |
AU2017382160A1 (en) | Pharmaceutical formulations of suvorexant | |
WO2010141068A1 (en) | Opthalmic compositions of cyclosporin | |
Sudareva et al. | Morphology of rat muscle tissue after implantation of delivery systems consisting of porous CaCO3 vaterites doped with dextran sulfate and containing doxorubicin | |
KR101771483B1 (ko) | 루테인의 용출률 및 안정성이 개선된 이중층 구조의 고분자 캡슐, 이의 제조방법 및 이를 함유하는 안과질환 예방 또는 치료용 약제학적 조성물 | |
CN104971351A (zh) | 药物组合物及其应用 | |
CN114732789B (zh) | 一种用于治疗肺动脉高压的复方长效递药系统及其制备 | |
CN112972391B (zh) | 一种胆红素-jph203纳米颗粒及其制备和应用 | |
KR102263606B1 (ko) | 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도 | |
US20230002566A1 (en) | Biodegradable polymeric compositions, methods of preparation and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517270 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005709250 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580005435.4 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005709250 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10586775 Country of ref document: US |